Search research articles

Search research articles

Related Experiment Videos

Experimental studies with isradipine in stroke.

A Sauter¹, M Rudin

¹Preclinical Research, Sandoz Pharma Ltd, Basle, Switzerland.

|January 1, 1990

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Brain mapping across 16 autism mouse models reveals a spectrum of functional connectivity subtypes.

Molecular psychiatry·2022

Same author

Brain mapping across 16 autism mouse models reveals a spectrum of functional connectivity subtypes.

Molecular psychiatry·2021

Same author

Multispectral Near-Infrared Optical Tomography for Cancer Hypoxia Study in Mice.

Advances in experimental medicine and biology·2018

Same author

Increasing isoflurane dose reduces homotopic correlation and functional segregation of brain networks in mice as revealed by resting-state fMRI.

Scientific reports·2018

Same author

Comparison of Errors of 35 Weight Estimation Formulae in a Standard Collective.

Geburtshilfe und Frauenheilkunde·2016

Same author

Transgenerational disruption of functional 5-HT<sub>1A</sub>R-induced connectivity in the adult mouse brain by traumatic stress in early life.

Molecular psychiatry·2016

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Isradipine effectively reduces stroke-related brain damage and neurological deficits in rats when administered shortly after an embolic stroke. This calcium channel blocker demonstrates potent cytoprotective effects, outperforming other drugs in reducing infarct size.

Area of Science:

Neuroscience
Pharmacology
Cardiovascular Research

Background:

Stroke remains a leading cause of disability and mortality worldwide.
Effective treatments for acute ischemic stroke are limited, necessitating research into novel therapeutic agents.
Calcium channel blockers are being investigated for their potential neuroprotective properties.

Purpose of the Study:

To evaluate the efficacy of isradipine in reducing infarct size and improving neurological deficits in a rat model of embolic stroke.
To compare the neuroprotective effects of isradipine with other calcium channel blockers.
To explore the mechanisms underlying isradipine's cytoprotective effects in stroke.

Main Methods:

Induction of permanent middle cerebral artery (MCA) occlusion in a rat model to simulate embolic stroke.

Related Experiment Videos

Administration of isradipine at various time points (onset to 4 hours post-stroke).

Assessment of infarct size using magnetic resonance imaging (MRI) and histology; evaluation of neurological deficits.

Main Results:

Isradipine significantly reduced infarct size when administered up to 4 hours after MCA occlusion.
Isradipine demonstrated superior efficacy in reducing infarct size compared to nimodipine, nicardipine, and flunarizine.
Isradipine treatment led to a parallel improvement in neurological deficits.
Isradipine, used as an antihypertensive, reduced infarct size by over 60% in spontaneously hypertensive rats, suggesting mechanisms beyond blood pressure normalization.

Conclusions:

Isradipine exhibits potent cytoprotective effects in an embolic stroke model, reducing infarct size and improving neurological outcomes.
Isradipine is a highly effective calcium channel blocker for stroke treatment, surpassing other agents in preclinical studies.
The neuroprotective mechanisms of isradipine in stroke warrant further investigation, with potential clinical implications for stroke management.